Stockreport
Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announces that numerous abstracts, including data from its clinical development programs for ruxolitinib (Jakafi®), itacitinib and ponatinib (Iclusig®) will be presented at the upcoming American Society of Hematology (ASH) Annual Meeting 2019 in Orlando, Florida from December 7-10, 2019.“We look forward to ASH 2019 and the opportunity to present data for our approved and late stage compounds from our oncology portfolio,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “These data strengthen the body of evidence supporting treatments that may deliver meaningful benefit for patients with rare cancers like polycythemia vera and myelofibrosis, leukemias and serious conditions such as graft-versus-host disease.”Select key abstract presentations include:Oral PresentationsRisk of Hemorrhage in Patients with Polycythemia Vera Exposed to Aspirin in Combination with Anticoagulants: Results of a Prospective, Multicenter, Observa
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | INCY | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
INCY alerts
INCY alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
NEWS
NEWS
- Incyte (NASDAQ:INCY) had its price target lowered by analysts at Royal Bank Of Canada from $95.00 to $92.00. They now have a "sector perform" rating on the stock.[MarketBeat]
- Incyte (NASDAQ:INCY) was given a new $102.00 price target on by analysts at Morgan Stanley.[MarketBeat]
- Incyte: Why The Market Is Overreacting To A Guidance 'Miss' [Seeking Alpha][Seeking Alpha]
- Incyte (NASDAQ:INCY) had its price target lowered by analysts at Wells Fargo & Company from $107.00 to $101.00. They now have an "equal weight" rating on the stock.[MarketBeat]
- Incyte (NASDAQ:INCY) was given a new $120.00 price target on by analysts at Stifel Nicolaus.[MarketBeat]
- More
INCY
SEC Filings
SEC Filings
- 2/10/26 - Form SCHEDULE
- 2/10/26 - Form 10-K
- 2/10/26 - Form 8-K
- INCY's page on the SEC website
- More